Biosimilar Monoclonal Antibodies Market: A Catalyst for Innovation and Increased Availability

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1218

According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies market is valued at US$ 4.98 Billion in 2021. It is expected to reach US$ 36.85 Billion by 2030, with a CAGR of 25% during a forecast period of 2024-2031.

In order to generate monoclonal antibodies (mAb), identical clones of the original progenitor cell's immune cells are utilized. As clones of the same parent cell, all monoclonal antibodies generated by a parent cell are identical and are therefore classified as biosimilar monoclonal antibodies. Among biotherapeutic products are biosimilars. They exhibit comparable quality, efficacy, and safety standards to state-of-the-art reference pharmaceutical products. mAb biosimilars are complex macromolecules of biology that have undergone a number of post-translational modifications. A multitude of chronic, inflammatory, and autoimmune disorders are efficaciously treated with these biosimilars.

The global market for biosimilar monoclonal antibodies is experiencing growth due to several factors, including the increasing prevalence of chronic diseases such as cancer, kidney failure, rheumatoid arthritis, psoriasis, and diabetes, the rising production of advanced monoclonal antibodies, and the aging population. In the future years, increasing opportunities for market expansion are expected as more patents for mAbs expire.

Increased patent expirations of the most widely used antibodies are anticipated to fuel rapid growth in the demand for mAbs over the forecast period. However, it is anticipated that the market's expansion will be hindered by the following factors: the intricacy of manufacturing biological pharmaceuticals, manufacturers' limited experience with clinical trials, stringent government regulations governing product approvals, and a lack of awareness and comprehension among producers regarding biosimilar regulation and approval.

During the forecast period, North America is anticipated to be the largest contributor to the market for biosimilar monoclonal antibodies. Increased product approvals, a firmly established health care infrastructure, and a favorable reimbursement environment have all contributed to the region's robust growth. Furthermore, substantial growth is anticipated in the Asia Pacific regional market over the projected period due to the increasing prevalence of chronic diseases, the demand for cost-effective treatments, and governmental funding for enhancements to healthcare facilities.

Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.

Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
• In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1218

Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2024-2031 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Ranibizumab
• Denosumab
• Eculizumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Other Pipeline Products

Global Biosimilar Monoclonal Antibodies Market, by Indication, 2024-2031 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication

Global Biosimilar Monoclonal Antibodies Market, by Region, 2024-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Biosimilar Monoclonal Antibodies Market, by Country, 2024-2031 (Value US$ Mn)
• U.S.
• Canada

Europe Biosimilar Monoclonal Antibodies Market, by Country, 2024-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2024-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2024-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2024-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
 To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
 To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
 To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1218

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.